BUSINESS

• Mochida Abandons Antidepressant MD-120, Lexapro’s Pediatric Use
  February 7, 2023

• Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
  February 7, 2023

• Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
  February 7, 2023

• Opdivo Extends Streak of Top-Seller Crown to 13 Months: Encise
  February 7, 2023

• Astellas EVP Okamura to Become CEO in April
  February 6, 2023

• Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
  February 6, 2023

• Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
  February 3, 2023

• Nobelpharma’s Nobelzin Granules Now Available, 2 Years after Approval
  February 3, 2023

• Takeda Joins Pilot Study of Robotic Drug Delivery Service in Tokyo
  February 3, 2023

• Roche/Chugai Drop Gantenerumab Alzheimer’s Program
  February 3, 2023

• Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
  February 3, 2023

• Tarlige Snatches Pole Position from Twymeeg in GP Promotion Ranking in December: Intage
  February 2, 2023

• Hemlibra Approved in Europe for Moderate Hemophilia A: Roche/Chugai
  February 2, 2023

• Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
  February 1, 2023

• Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
  February 1, 2023

• Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
  February 1, 2023

• Jardiance Filed in Japan for Chronic Kidney Disease: BI/Lilly
  February 1, 2023

• Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
  February 1, 2023

• Boehringer Ingelheim in AMD Collab with Jichi Medical University
  January 31, 2023

• BMS, Kyoto University Join Hands to Deliver Innovative Drugs
  January 31, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 158
• 159
• 160
• 161
• 162
• 163
• 164
• 165
• 166
• …
• Next ›
• 最終 »